ID   IGR-CaP1-R100
AC   CVCL_IR45
DR   cancercelllines; CVCL_IR45
DR   Wikidata; Q54897377
RX   Patent=US8674172;
RX   PubMed=24525428;
CC   Group: Patented cell line.
CC   Registration: International Depositary Authority, Pasteur Institute Collection Nationale de Cultures de Micro-organismes (CNCM); I-4127.
CC   Selected for resistance to: ChEBI; CHEBI:4672; Docetaxel anhydrous (Taxotere).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Prostate; UBERON=UBERON_0002367.
ST   Source(s): Patent=US8674172
ST   Amelogenin: X
ST   CSF1PO: 11,12,14,15,16
ST   D13S317: 8,10
ST   D16S539: 10,11,12,13
ST   D18S51: 15,16
ST   D19S433: 13,14
ST   D21S11: 26,30.2
ST   D2S1338: 17,24,25
ST   D3S1358: 14,15
ST   D5S818: 12,13
ST   D7S820: 9.1,10.1,11.2
ST   D8S1179: 13,14,16,17
ST   FGA: 19,20,21,25
ST   TH01: 6,7,8,9.3
ST   TPOX: 8,10,11
ST   vWA: 16,20,21
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_A018 ! IGR-CaP1
SX   Male
AG   58Y
CA   Cancer cell line
DT   Created: 03-03-17; Last updated: 05-10-23; Version: 10
//
RX   Patent=US8674172;
RA   Chauchereau A., Fizazi K., Gaudin C., Al Nakouzi N., Benard J.;
RT   "Prostate cancer cell lines and their use in screening method.";
RL   Patent number US8674172, 18-Mar-2014.
//
RX   PubMed=24525428; DOI=10.18632/oncotarget.1574;
RA   Al Nakouzi N., Cotteret S., Commo F., Gaudin C., Rajpar S., Dessen P.,
RA   Vielh P., Fizazi K., Chauchereau A.;
RT   "Targeting CDC25C, PLK1 and CHEK1 to overcome docetaxel resistance
RT   induced by loss of LZTS1 in prostate cancer.";
RL   Oncotarget 5:667-678(2014).
//